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Abstract
Background: The tumor-associated calcium signal transducer (TACSTD) genes, originally designated epithelial cell
adhesion molecule (EpCAM) and TROP2, represent true oncogenes. Little is known about EpCAM and TROP2 gene
expression in non-small cell lung carcinoma (NSCLC). This study evaluated EpCAM and TROP2 protein expression
and clinicopathologic significance in cases of NSCLC.
Methods: Tissue microarray blocks acquired from 164 cases of NSCLC, including 100 cases of adenocarcinoma
(AdC) and 64 of squamous cell carcinoma (SCC), were examined by immunohistochemical staining for EpCAM, and
TROP2. The results were correlated with clinicopathologic data.
Results: EpCAM and TROP2 were significantly overexpressed in SCC than in AdC (P < 0.01). In AdC, EpCAM
overexpression was closely related to sex, histologic grade, pathologic T stage, pathologic N stage, and TNM stage,
and TROP2 overexpression was only related to histologic grade (P < 0.05, respectively). In SCC, correlations were
evident between EpCAM overexpression and TNM stage (P = 0.01), and between TROP2 overexpression and
pathologic T stage (P = 0.02). EpCAM overexpression showed no significance with overall survival in AdC and SCC
patients. However, TROP2 overexpression in AdC had a positive influence on overall survival (P = 0.02) and disease-
free survival (P = 0.03). In particular, AdC patients with stage II or III showed better overall survival (P = 0.05) and
disease-free survival (P = 0.04).
Conclusions: While EpCAM and TROP2 show weak and non-complete membranous staining in normal bronchial
epithelium and pneumocyte, their complete membranous expression in carcinoma suggests their role in
carcinogenesis. EpCAM and TROP2 were more frequently overexpressed in SCC. EpCAM overexpression had no
prognostic value in this study, but TROP2 overexpression showed better survival in AdC patients and might be a
better prognostic marker in advanced stage AdC.
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Background
Non-small cell lung carcinoma (NSCLC) is a major cause
of cancer-related death in bothmen and women globally
[1]. Despite recent advancements in early tumor detec-
tion, surgical treatment, radiochemotherapy, and targeted
therapy, the NSCLC-related high mortality rate remains a
daunting challenge [2]. For example, targeted NSCLC
therapy, especially against epidermal growth factor recep-
tor (EGFR), has advanced greatly, yet only approximately
15% of NSCLCs experience therapeutic benefits due to
various factors [3]. Since no single marker is sufficient
for prediction of prognosis, many studies have focused
on the development of new biomarkers.
The tumor-associated calcium signal transducer
(TACSTD) gene family consists of two highly conserved
and closely related genes, TACSTD1 and TACSTD2,w h i c h
map to chromosomes 2p21[4] and 1p32[5], respectively.
The TACSTD1 gene encodes TROP1, which was originally
designated as epithelial cell adhesion molecule (EpCAM).
TROP1 is a 39-42 kDa, 314 amino acid, type l transmem-
brane glycoprotein. EpCAM mediates epithelium-specific,
Ca
2+-independent homotypic cell-cell adhesion and repre-
sents the first human tumor associated antigen to be dis-
covered. It has been used as an immunotherapeutic target
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lateral surface of normal simple, pseudostratified, and tran-
sitional epithelia. It is also overexpressed in various human
carcinomas, including those of the colon and rectum, pros-
tate, liver, esophagus, lung, head and neck, pancreas, and
breast [6]. EpCAM participates as a cell adhesion and cell
signaling molecule, and its overexpression negatively corre-
lates with survival rates in gallbladder cancer, ampullary
carcinoma, and squamous cell carcinoma (SCC) of the
head and neck [4,7]. EpCAM expression is also associated
with better survival in clear cell renal cell carcinoma
patients [8] and is related to shortened survival in node-
positive breast cancer patients [9].
TROP2 is a 35 kDa, 323 amino acid, type 1 transmem-
brane protein with a single transmembrane domain [10].
TROP2, which was originally identified in human tropho-
blast and choriocarcinoma cell lines [11], is encoded by
TACSTD2. TROP2 is not expressed in normal tissue, but
is overexpressed in many carcinomas, including colorec-
tal cancer, gastric cancer, SCC of the oral cavity, and pan-
creatic cancer [5]. Like EpCAM, TROP2 has been an
attractive immunotherapeutic target in cancer treatment.
Recently, TROP2 has been actively studied as a prognos-
tic marker for various cancers. TROP2 overexpression
has been associated with poor prognosis in colon cancer
[10] and oral SCC [11].
Although the roles of EpCAM and TROP2 are not yet
fully understood, both proteins are thought to participate
in growth and proliferation of carcinoma cells. EpCAM
can transduce an intracellular signal through its cleavage
of an intracytoplasmic portion [7]. TROP2 is also believed
to be a true oncogene involved in initiating signaling
mechanisms that can result in increased tumorigenicity,
aggressiveness, and metastasis [5]
The present study focused on the differential expression
of EpCAM and TROP2 according to SCC or adenocarci-
noma (AdC) histology, because certain genetic lesions may
play different biological roles depending on the histological
subtypes [12]. The study evaluated EpCAM and TROP2
expression in regard to various clinicopathologic factors
and survival to investigate their potentials as biomarkers,
and also analyzed the prognostic significance of the status.
Methods
Clinicopathologic data of NSCLC patients
All NSCLC patients who underwent lobectomy or pneu-
monectomy at Pusan National University Hospital,
Busan, Korea from July 2000 to December 2009 were
enrolled in this study. After exclusion of cases in which
there were insufficient pathological materials remaining
for further study, a total of 164 cases (113 men and 51
women; mean age 63.4 years; range 42-81 years) were
selected. The patients were followed up from the date of
surgery until death or the last visit to the outpatient
department (median follow-up 39.4 months; range 1-123
months). At the time of the last follow-up, 129 patients
(78.7%) were alive and 35 patients (21.3%) had died.
Tumors were staged according to the TNM classification
of the International Union Against Cancer staging system
after review of the clinical, radiological, and pathological
data. Other clinical information was extracted from med-
ical records and further clincopathologic characteristics
of the patients are summarized in Tables 1 and 2. There
were 64 cases of SCC and 100 cases of AdC.
Immunohistochemistry
Sections from TMA blocks were transferred to poly-L-
lysine-coated glass slides. They were dewaxed in xylene,
rehydrated in ethanol. Endogenous peroxidase activity was
inactivated with 5% hydrogen peroxide in methanol for
15 min at room temperature. Antigen retrieval was per-
formed using a cooker for 40 min at 95°C in citrate for
mouse monoclonal anti-EpCAM antibody (ESA, clone
VU-1D9; Novocastra, Newcastle upon Tyne, UK). Pronase
treatment was carried out for purified goat polyclonal anti-
body against the recombinant human TROP2 extracellular
domain (AF650; R&D Systems, Minneapolis, MN, USA).
Antibody was incubated with the tissue sections at room
temperature for 1 h. The dilutions used were 1:400 for
EpCAM, and 1:50 for TROP2. For the detection of
EpCAM antibody signals, an Envision detection kit (Dako-
Cytomation, Glostrup, Denmark) was used. Labeling for
TROP2 was done with ABC reagent (Vectastain Elite ABC
Kit Standard PK-6100; Vector Labs, Burlingame, CA,
USA). Reaction products were visualized by exposing sec-
tions to diaminobenzidine. Nuclei were lightly counter-
stained with Mayer’sh e m a t o x y l i n .
Immunohistochemistry scoring
TMA slides were evaluated by two independent observers
using light microscopy in a blinded fashion. Discordant
cases were re-evaluated on a multiheaded microscope to
achieve a consensus. For EpCAM, only complete membra-
nous staining was considered for scoring. For each tumor
sample, staining intensity (0, 1+, 2+, 3+) and percentage of
positive tumor cells were estimated. Results were grouped
as follows: negative (total absence of staining), weak (1+
staining in < 60% of cells or 2+ staining in < 30% of cells),
moderate (1+ staining in ≥ 60% of cells, 2+ staining in 30%
to 70%, or 3+ staining in < 30%), and strong (2+ staining
in > 70% or 3+ staining in ≥ 30%) [6]. EpCAM overexpres-
sion was defined as moderate and strong immunoactivity.
TROP2 expression was defined as the presence of specific
staining on the surface membrane of tumor cells. TROP2
expression was evaluated for each tissue sample by calcu-
lating a total immunostaining score as the product of a
proportion and intensity score. The proportion score
described the estimated fraction of positively stained
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Page 2 of 8Table 1 EpCAM and Trop2 overexpression in relation to clinicopathologic factors in adenocarcinoma
Parameter Number EpCAM overexpression P value Trop2 overexpression P value
Sex
Male 52 26 (50.0) 0.019 13 (25.0) 0.621
Female 48 13 (27.1) 10 (20.8)
Age at diagnosis 100 0.490 0.102
Histologic grade
Well differentiated 42 7 (16.7) 0.000 5 (11.9) 0.015
Moderately differentiated 38 15 (39.5) 9 (23.7)
Poorly differentiated 20 17 (85.0) 9 (45.0)
T stage
pT1 68 21 (30.9) 0.015 21 (24.7) 0.335
pT2, 3, 4 32 18 (56.3) 2 (13.3)
N stage
pN0 80 27 (33.8) 0.031 17 (21.3) 0.406
pN1, 2, 3 20 12 (60.0) 6 (30.0)
TNM stage
I 68 21 (30.9) 0.050 15 (22.1) 0.70
II, III 32 18 (56.3) 8 (25.0)
Smoking 81
Never 39 11 (28.2) 0.085 7 (17.9) 0.947
Quit 19 7 (36.8) 4 (21.1)
Current 23 13 (56.5) 4 (17.4)
Smoking (PY) 79 0.376 0.441
Table 2 EpCAM and Trop2 overexpression in relation to clinicopathologic factors in squamous cell carcinoma
Parameter Number EpCAM overexpression P value Trop2 overexpression P value
Sex
Male 61 52 (85.2) 0.473 40 (65.6) 0.256
Female 3 3 (100.0) 1 (33.3)
Age at diagnosis 64 0.095 0.310
Histologic grade
Well differentiated 7 6 (85.7) 0.815 6 (85.7) 0.240
Moderately differentiated 41 36 (87.8) 27 (65.9)
Poorly differentiated 16 13 (81.3) 8 (50.0)
T stage
pT1 56 49 (87.5) 0.341 33 (58.9) 0.024
pT2, 3, 4 8 6 (75.0) 8 (100.0)
N stage
pN0 39 32 (82.1) 0.264 26 (66.7) 0.588
pN1, 2, 3 25 23 (92.0) 15 (60.0)
TNM stage
I 29 26 (89.7) 0.494 19 (65.5) 0.963
II, III 35 29 (82.9) 22 (62.9)
Smoking 55
Never 7 5 (71.4) 0.303 6 (85.7) 0.362
Quit 18 17 (94.4) 10 (55.6)
Current 30 25 (83.3) 18 (60.0)
Smoking (PY) 55 0.182 0.425
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Page 3 of 8tumor cells (0 = none; 1 ≤ 10%; 2 = 10-50%; 3 = 51-80%;
4 ≥ 80%). The intensity score represented the estimated
staining intensity (0, no staining; 1, weak; 2, moderate; 3,
strong). The total score ranged from 0 to 12. TROP2 over-
expression was arbitrarily defined as a total score > 4 [11].
Statistical analyses
Pearson Chi-square test or Fisher’s exact test was used to
evaluate the statistical significance of immunohistochem-
ical results related to clinicopathological parameters.
Mann-Whitney test was used for continuous variables.
Follow-up information was also obtained for survival
analysis. Patient survival was calculated as the time
between operation and death. Patients who were still
alive at the time of data collection were censored in the
statistical analyses. The cases lost to follow-up or deaths
from any other cause were defined as censored data for
the analysis of survival rates. The survival curves were
plotted using the Kaplan-Meier method, and P values
were calculated using the log-rank test. All statistical ana-
lyses were performed on a personal computer with the
SPSS version 15.0 statistical package (SPSS, Chicago, IL,
USA). A P value < 0.05 was regarded as statistically
significant.
Results
EpCAM and TROP2 expression in normal bronchial
epithelium
Immunoreactivity of EpCAM and TROP2 was evaluated
in 164 patents with NSCLC. EpCAM was expressed at
the basolateral surface of nonneoplastic bronchial
mucosa and TROP2 was absent or infrequently expressed
in this location (Figure 1). Neither protein was expressed
in pneumocytes.
EpCAM expression in NSCLC
EpCAM showed complete membranous expression in car-
cinoma. From 100 AdC samples, 45 (45.0%) showed no
immunoreactivity, 16 (16.0%) showed weak expression,
17 (17.0%) showed moderate expression, and 22 (22.0%)
showed strong expression, accounting for an overexpres-
sion rate of 39 (39.0%) (Figure 2). From 64 SCC samples,
six (9.3%) showed weak expression, 10 (15.6%) showed
moderate expression, 45 (70.3%) showed strong expres-
sion, and only three (4.7%) showed no immunoreactivity,
accounting for an overexpression rate of 55 (85.9%) (Fig-
ure 2). EpCAM was more frequently overexpressed in
SCC than AdC (P < 0.01) (Table 3).
TROP2 expression in NSCLC
Immunohistochemical studies in 100 AdC samples
revealed no expression (total score 0) in 53 (53.0%),
weak expression (total score 1-4) in 24 (24.0%), moder-
ate expression (total score 6 and 8) in 14 (14.0%), and
strong expression (total score 9 and 12) in nine (9.0%).
Thus, according to the aforementioned criteria, TROP2
was overexpressed in 23 (23.0%) of the AdC cases (Fig-
ure 3). In the 64 SCC cases, seven (10.9%) showed a
lack of expression, 16 (40.6%) showed weak expression,
15 (23.4%) showed moderate expression, and 26 (32.9%)
showed strong expression. TROP2 overexpression was
noted in 41 (64.1%) of the SCC cases (Figure 3). TROP2
overexpression was significantly more frequent in SCC
(P < 0.01) (Table 3).
EpCAM and TROP2 overexpression and their correlation
with clinicopathologic factors
Univariate analysis of EpCAM overexpression in relation
to sex, age at diagnosis, tumor differentiation, pathologic
T stage, lymph node metastasis, TNM stage, and smoking
status revealed that in AdC, EpCAM overexpression was
significantly associated with sex, tumor differentiation,
pathologic T stage, lymph node metastatis, and TNM
stage. In contrast, EpCAM overexpression was not signifi-
cantly related to age at diagnosis and smoking status
(Table 1). TROP2 overexpression was only associated with
tumor differentiation. There was no statistical significance
between TROP2 overexpression and sex, age at diagnosis,
Figure 1 Immunohistochemical expression of EpCAM and TROP2 in normal bronchial mucosa.( A) EpCAM is expressed on the basolateral
surface. (B): TROP2 shows a similar expression pattern.
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and smoking status (Table 1). In SCC, EpCAM overex-
pression was not related to clinicopathologic factors.
T R O P 2s h o w e das i g n i f i c a n tr elationship only with the
pathologic T stage (Table 2).
EpCAM and TROP2 overexpression and correlation with
overall survival
TROP2 overexpression showed better overall survival in
AdC patients by Kaplan-Meier analysis (median follow-up
39.6 months; range 2-123 months) (P = 0.02) (Figure 4A).
Stage II or III AdC patients with TROP2 overexpression
showed better overall survival (P =0 . 0 5 )( F i g u r e4 B ) .I n
SCC patients, TROP2 overexpression revealed a trend of
better overall survival although it was not significant statis-
tically (P = 0.49). EpCAM expression was also not related
with overall survival in AdC (P = 0.23) or SCC (P = 0.61).
It showed only a tendency of better survival.
EpCAM and TROP2 overexpression and correlation with
disease-free survival
TROP2 overexpression showed better disease-free survival
in AdC patients (P = 0.03) (Figure 4C). Better disease-free
survival was observed in stage II or III AdC patients with
TROP2 overexpression (P = 0.04) (Figure 4D). In SCC
patients, TROP2 overexpression is not associated with dis-
ease free survival (P = 0.39). However, disease-free survival
was not statistically related with EpCAM expression in
both histologies (AdC, P = 0.31; SCC, P = 0.60).
Multivariate survival in AdC
In univariate survival tests with clinicopathologic factors in
AdC, statistically significant were age (P = 0.001), T stage
(P = 0.007), TNM stage (P = 0.035) besides TROP2
expression. Other variables including sex, tumor differen-
tiation, N stage, and smoking history were not associated
with better survival. Multivariate survival test was done
with age, T stage TNM stage, and TROP2 expression.
Only T stage (P = 0.033) showed significance.
Discussion
Although the EpCAM and TROP2 proteins were discov-
ered some time ago, only recently have they become the
focus of research in various cancers. While there are
increasing reports about the role of EpCAM or TROP2 in
various cancers, only a few reports of EpCAM or TROP2
expression in NSCLC have been published [2,13]. In one
recent study, EpCAM expression was investigated in
NSCLC, but TROP2 was not involved [2]. A study by
Kobayashi et al. has evaluated TROP2 expression in
NSCLC [13], and it was limited to small-sized AdC.
Hence, the present study is the first comprehensive evalua-
tion of the expression of EpCAM and TROP2 in pulmon-
ary AdC and SCC, simultaneously.
Figure 2 Immunohistochemical staining for EpCAM. Note the membranous staining of tumor cells. EpCAM expression in adenocarcinoma,
without expression (A) and with weak (B), moderate (C), and intense (D) expression. EpCAM expression in squamous cell carcinoma, without
expression (E), with weak (F), moderate (G), and intense (H) expression.
Table 3 EpCAM and TROP2 overexpression according to adenocarcinoma or squamous cell carcinoma
EpCAM expression TROP2 expression
Low Over P value Low Over P value
Adenocaricnoma 61 (61.0) 39 (39.0) 0.000 77 (77.0) 23 (23.0) 0.000
SCC 9 (14.1) 55 (85.9) 23 (35.9) 41 (64.1)
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EpCAM and TROP2 expression between in normal bron-
chial epithelium and in NSCLC. In normal bronchial
epithelium, both proteins showed only infrequent
basolateral cytoplasmic membrane positivity. They were
not stained in alveolar pneumocytes. As EpCAM is a
cell-cell adhesion molecule in epithelial cells, its distribu-
tion along the cytoplasmic membrane is not unexpected.
Figure 3 Immunohistochemical staining for TROP2. Note the membranous staining of tumor cells. TROP2 expression in adenocarcinoma,
without expression (A) and with weak (B), moderate (C), and intense (D) expression. TROP2 expression in squamous cell carcinoma, without
expression (E) and with weak (F), moderate (G), and intense (H) expression.
Figure 4 Kaplan-Meier survival curves.( A) Overall survival according to Trop2 overexpression in adenocarcinoma (AdC). (B) Overall survival
according to according to Trop2 overexpression in stage II or III AdC. (C) Disease-free survival according to Trop2 overexpression in AdC. (D)
Disease-free survival according to Trop2 overexpression in stage II or III AdC.
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Page 6 of 8On the other hand, EpCAM and TROP2 were overex-
pressed in NSCLC and their staining along the cytoplas-
mic membrane was complete along the membrane. This
finding corroborates a previous report that the expres-
sion of EpCAM increases in a stepwise manner from
uninvolved bronchial mucosa, epithelial hyperplasia, to
SCC [2]. Cytoplasmic or nuclear expression was not seen
in our study. Although Kobayashi et al. advocated that
TROP2 is also expressed in cytoplasm in NSCLC [13]
and we observed focal cytoplasmic staining, we think that
this is non-specific staining regarding that cytoplasmic
expression was only focally observed in the cases which
show strong membranous TROP2 staining. Both EpCAM
and TROP2 were more frequently expressed in SCC in
the present study, being consistent with a previous study
[6]. But, the pattern of expression was not different to
each other. Besides functioning as cell-cell adhesion
molecule, EpCAM has been recently known to act as an
oncogene, proving to trasduce cell proliferating signal
through c-myc, cyclin D, and survivin. In another aspect,
the loss of EpCAM has been advocated to promote
tumor progression through weakening cell-cell adhesion.
When EpCAM is overexpressed, some cancers such as
stage I or II gastric cancer, stage II NSCLC, clear cell
renal cell carcinoma, and stage II colon cancer show bet-
ter survival while others such as node-positive breast
cancer, epithelial ovarian cancer, gall bladder cancer,
cholangiocarcinoma, ampullary pancreas cancer, squa-
mous cell cancer of the esophagus, and squamous cell
head and neck cancer do worse. This contradicting result
may be determined by which function of cell-cell adhe-
sion or oncogene of EpCAM predominates. Although the
function of TROP2 is less defined than that of EpCAM,
TROP2 has also been suggested as oncogene, promoting
cancer cell proliferation and migration, and cell adhesion
molecule [5,14]. Regarding NSCLC, Kobayashi et al.
reported that TROP2 overexpression in small pulmonary
AdC was related with worse overall survival [13]. How-
ever, in our study, TROP2 overexpression was related
with better overall survival and disease free survival in
AdC, although SCC showed same tendency but no statis-
tical significance. To our best knowledge, there has not
been a study, in which TROP2 overexpression in cancer
was associated with better survival than those which do
not. This discordance between our study and previous
one may be partially explained by that Kobayashi et al.
included only AdC which are < 2 cm in size, while we
included larger tumors of varying degree of differentia-
tion. In our study, stage II or III AdC with TROP2 over-
expression showed better overall survival and disease-
free survival while in stage I AdC, TROP2 overexpression
did not affect overall survival or disease-free survival.
Furthermore, poorly differentiated AdCs expressed
T R O P 2m o r ef r e q u e n t l y .T h e s ed a t ai m p l yt h a tp o o r l y
differentiated AdCs may show better survival when they
express TROP2. Whether TROP2 serves as an adhesion
molecule or not has not been fully defined. Some advo-
cated its role as adhesion molecule [15], but early study
could not prove it [16]. Recently, it has been discovered
that TROP2 binds with Claudin 1 and 7 which are
important components of tight junctions, taking part in
cell-cell adhesion [17]. Hence, we hypothesized that the
biologic role of TROP2 can be different in early and
advanced pulmonary AdC. In higher stage pulmonary
AdC, the role of TROP2 as an adhesion molecule may be
greater than as an oncogene. TROP2 overexpression may
strengthen bonds between tumor cells, preventing their
shedding and progression. Like EpCAM showed variable
results in variable cancers, TROP2 may play different
roles in different cancers.
Conclusions
The EpCAM and TROP2 proteins are expressed in
NSCLC, and only weakly or not expressed in normal
lung tissue. The expression pattern of EpCAM and
TROP2 was similar in SCC and AdC. TROP2 protein did
confer a significant survival effect in AdC. This finding
may reflect that TROP2 is involved in cell-cell adhesion
in pulmonary AdC and its loss will promote tumor cell
shedding. Hence, our study showed that TROP2 predicts
better prognosis in AdC of NSCLC.
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